Considering the important role of gut microbiota in both preclinical NAFLD/NASH models and patients with NASH, the role of STING and gut microbiota interaction in modulating intrahepatic inflammation is still significant to explore. This evidence concerns the gene STING1 and metabolic dysfunction-associated steatotic liver disease.